BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by a defective skin barrier function. Recent studies have reported mutations of the skin barrier gene encoding filaggrin in a subset of patients with AD. OBJECTIVE: We investigated whether reduced filaggrin expression was found in patients with AD who were not carriers of known filaggrin mutations and whether filaggrin expression was modulated by the atopic inflammatory response. METHODS: Filaggrin expression was measured in skin biopsies and cultured keratinocytes using real-time RT-PCR and immunohistochemistry. Filaggrin loss-of-function mutations were screened in a total of 69 subjects. RESULTS: Compared with normal skin, filaggrin expression was significantly reduced (P < .05) in acute AD skin, with further reduction seen in acute lesions from 3 European American subjects with AD who were heterozygous for the 2282del4 mutation. This was confirmed by using immunohistochemistry. AD skin is characterized by the overexpression of IL-4 and IL-13. Keratinocytes differentiated in the presence of IL-4 and IL-13 exhibited significantly reduced filaggrin gene expression (0.04 +/- 0.01 ng filaggrin/ng glyceraldehyde 3-phosphate dehydrogenase; P < .05) compared with media alone (0.16 +/- 0.03). CONCLUSION: Patients with AD have an acquired defect in filaggrin expression that can be modulated by the atopic inflammatory response. CLINICAL IMPLICATIONS: The atopic immune response contributes to the skin barrier defect in AD; therefore, neutralization of IL-4 and IL-13 could improve skin barrier integrity.
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by a defective skin barrier function. Recent studies have reported mutations of the skin barrier gene encoding filaggrin in a subset of patients with AD. OBJECTIVE: We investigated whether reduced filaggrin expression was found in patients with AD who were not carriers of known filaggrin mutations and whether filaggrin expression was modulated by the atopic inflammatory response. METHODS: Filaggrin expression was measured in skin biopsies and cultured keratinocytes using real-time RT-PCR and immunohistochemistry. Filaggrin loss-of-function mutations were screened in a total of 69 subjects. RESULTS: Compared with normal skin, filaggrin expression was significantly reduced (P < .05) in acute AD skin, with further reduction seen in acute lesions from 3 European American subjects with AD who were heterozygous for the 2282del4 mutation. This was confirmed by using immunohistochemistry. AD skin is characterized by the overexpression of IL-4 and IL-13. Keratinocytes differentiated in the presence of IL-4 and IL-13 exhibited significantly reduced filaggrin gene expression (0.04 +/- 0.01 ng filaggrin/ng glyceraldehyde 3-phosphate dehydrogenase; P < .05) compared with media alone (0.16 +/- 0.03). CONCLUSION: Patients with AD have an acquired defect in filaggrin expression that can be modulated by the atopic inflammatory response. CLINICAL IMPLICATIONS: The atopic immune response contributes to the skin barrier defect in AD; therefore, neutralization of IL-4 and IL-13 could improve skin barrier integrity.
Authors: Michael D Howell; Mark Boguniewicz; Saveria Pastore; Natalija Novak; Thomas Bieber; Giampiero Girolomoni; Donald Y M Leung Journal: Clin Immunol Date: 2006-10-02 Impact factor: 3.969
Authors: Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung Journal: N Engl J Med Date: 2002-10-10 Impact factor: 91.245
Authors: Ichiro Nomura; Elena Goleva; Michael D Howell; Quatyba A Hamid; Peck Y Ong; Clifton F Hall; Marc A Darst; Bifeng Gao; Mark Boguniewicz; Jeffrey B Travers; Donald Y M Leung Journal: J Immunol Date: 2003-09-15 Impact factor: 5.422
Authors: Donald Y M Leung; Mark Boguniewicz; Michael D Howell; Ichiro Nomura; Qutayba A Hamid Journal: J Clin Invest Date: 2004-03 Impact factor: 14.808
Authors: Carlos F Santillan Salas; Sonia Mehra; Maria R Pardo Crespo; Young J Juhn Journal: Allergy Asthma Proc Date: 2013 Sep-Oct Impact factor: 2.587
Authors: Shauna Schroeder; Zachary D Robinson; Joanne C Masterson; Lindsay Hosford; Wendy Moore; Zhaoxing Pan; Rachel Harris; Rhonda F Souza; Stuart Jon Spechler; Sophie A Fillon; Glenn T Furuta Journal: Pediatr Res Date: 2013-02-05 Impact factor: 3.756
Authors: Dirkjan Hijnen; Edward F Knol; Yoony Y Gent; Barbara Giovannone; Scott J P Beijn; Thomas S Kupper; Carla A F M Bruijnzeel-Koomen; Rachael A Clark Journal: J Invest Dermatol Date: 2012-12-06 Impact factor: 8.551